Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

IGC Pharma (IGC) Income from Non-Controlling Interests (2016 - 2018)

IGC Pharma (IGC) has disclosed Income from Non-Controlling Interests for 9 consecutive years, with $633.0 as the latest value for Q1 2018.

  • On a quarterly basis, Income from Non-Controlling Interests rose 105.02% to $633.0 in Q1 2018 year-over-year; TTM through Jun 2018 was $319.0, a 103.43% increase, with the full-year FY2017 number at $14399.0, up 156.02% from a year prior.
  • Income from Non-Controlling Interests was $633.0 for Q1 2018 at IGC Pharma, up from -$230.0 in the prior quarter.
  • In the past five years, Income from Non-Controlling Interests ranged from a high of $38088.0 in Q4 2016 to a low of -$42146.0 in Q4 2015.
  • A 5-year average of -$3091.5 and a median of -$319.0 in 2017 define the central range for Income from Non-Controlling Interests.
  • Peak YoY movement for Income from Non-Controlling Interests: plummeted 6461.33% in 2014, then skyrocketed 450.89% in 2015.
  • IGC Pharma's Income from Non-Controlling Interests stood at $8882.0 in 2014, then plummeted by 574.51% to -$42146.0 in 2015, then soared by 190.37% to $38088.0 in 2016, then plummeted by 100.6% to -$230.0 in 2017, then surged by 375.22% to $633.0 in 2018.
  • Per Business Quant, the three most recent readings for IGC's Income from Non-Controlling Interests are $633.0 (Q1 2018), -$230.0 (Q4 2017), and -$84.0 (Q3 2017).